N/A N=400 Study of the CAT RX Aspiration Catheter When Used in Patients With Large Occlusive Thrombus in Coronary Arteries
Coronary Vessel Occlusion
Primary: Composite of: — 14 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=131 A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Non-Hodgkin's Lymphoma
Primary: Percentage of Participants With CR at EOI Determined by an Independent Review Committee (IRC) on the Basis of Positron Emission Tomography (PET) and Computed Tomography…
Phase 3 N=51 Olive Oil for High Risk Breast Cancer Prevention in Women
Breast Cancer
Primary: Change in Maximum Volumetric Breast Density Percentage — -0.038 Mean decrease in max VBD percentage
Phase 3 N=35 A Study in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema to Evaluate the Safety of the Faricimab Prefilled Syringe
Neovascular Age-related Macular Degeneration · Diabetic Macular Edema
Primary: Percentage of Injection Procedures With Successful Completions on Critical Tasks Performed by Healthcare Providers in the Use of the Faricimab Prefilled Syringe…
Phase 2 N=30 Busulfan, Etoposide, and Total-Body Irradiation in Treating Patients Undergoing Donor Stem Cell or Bone Marrow Transplant for Advanced Hematologic Cancer
Leukemia · Myelodysplastic Syndromes
Primary: Overall Survival at 5 Years Post-Transplant. — 40 percentage of survival probability
N/A N=250 RVA Breathes: A Richmond City Collaboration to Reduce Pediatric Asthma Disparities
Asthma
Primary: Child Health Care Utilization — .0023; .0032; .0021 ED visits and hospitalizations
Phase 1 N=12 Study to Evaluate the Effect of Multiple-Dose Ritlecitinib on the Pharmacokinetics (PK) of Tolbutamide
Healthy Volunteers
Primary: Maximum Plasma Concentration (Cmax) of Tolbutamide Administered With and Without Ritlecitinib — 44240; 45740 ng/mL (nanogram/milliliter)
N/A N=40 Transcranial Direct Current Stimulation for the Treatment of Deficits After Traumatic Brain Injury
Traumatic Brain Injury · Post Concussive Symptoms · Depression
Primary: Examiner Score — 0.617; 0.907; 0.865; 1.155 score on a scale
Phase 1 N=14 A Study to Investigate the Influence of Hepatic Impairment on Elpipodect (MK-8189) Treatment (MK-8189-012)
Hepatic Impairment
Primary: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of MK-8189 — 5600; 4710 h*nmol/L
Phase 2 N=30 Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer
Metastatic Triple Negative Breast Cancer
Primary: Overall Response Rate (ORR) in Patients Treated With CNP — 2; 11; 6; 8 Participants
Phase 1 N=45 Investigation of Cocaine Addiction Using mGluR5 PET and fMRI
Cocaine Dependence
Primary: Regional Availability of Metabotropic Glutamate Type-5 Receptors (mGluR5) — 36.48; 32.19; 25.67; 22.41 mL*cm^3 — p=0.035
N/A N=57 Feasibility and Effect of a Strategy-Based Cognitive Intervention for Parkinson Disease
Parkinson Disease
Primary: Change in Bangor Goal Setting Interview (BGSI) Goal Attainment — 4.5; 4.6; 5.9; 7.4 score on a scale
N/A N=53 Theta Burst Transcranial Magnetic Stimulation of Fronto-parietal Networks: Modulation by Mental State
Healthy
Primary: 2-back Minus 1-back Blood Oxygen Level-Dependent (BOLD) Activation, Voxelwise in FPN — 0.74; 0.75; 0.58 arbitrary units — p==0.11
N/A N=4 TheraSphere® For Treatment of Metastases in Liver
Colorectal Cancer Metastatic · Colorectal Cancer
Primary: Number of Patients That Met the Criterion That the Dose Estimated With Tc-99m MAA SPECT Was Within 15% of the Dose Estimated From Y-90 SPECT — 4 Participants
Phase 3 N=2,357 A Study to Evaluate the Safety and Immunogenicity of Vaccine CVnCoV in Healthy Adults in Germany for COVID-19
Coronavirus · Covid19 · SARS-CoV-2
Primary: Number of Participants Who Experienced a Medically Attended Adverse Event (AE) Occurring in the Following 6 Months After Dose 2 — 95; 133; 58; 34 Participants